EGFR tyrosine kinase inhibitors (TKI) were approved for NSCLC patients harboring either of the two classic EGFR mutations, L858R and exon 19 deletion. The sensitivity profile of mutations other than these two classic EGFR mutations in response to different generations of EGFR-TKI has been reported. However, treatment response and survival outcomes of patients with some rare mutations are poorly understood. In our study, we aimed to investigate the survival outcome of NSCLC patients with rare EGFR mutations.